MCF Advisors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

MCF Advisors’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-40	Closed	–	–	502
2019 Q4	$0	Sell	40 -40	-50%	-$97	﹤0.01%	489
2019 Q3	$0	Hold	80	–	–	﹤0.01%	470
2019 Q2	$1K	Hold	80	–	–	﹤0.01%	438
2019 Q1	$0	Hold	80	–	–	﹤0.01%	496
2018 Q4	$0	Hold	80	–	–	﹤0.01%	513
2018 Q3	$2K	Hold	80	–	–	﹤0.01%	453
2018 Q2	$3K	Hold	80	–	–	﹤0.01%	401
2018 Q1	$3K	Hold	80	–	–	﹤0.01%	406
2017 Q4	$6K	Buy	+80	New	+$5.92K	﹤0.01%	372

MCF Advisors's MLNT Position: Q1 2020 in Review

MCF Advisors sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 40 shares.

MCF Advisors first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $6K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

MCF Advisors reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
MCF Advisors sold 40 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020.
MCF Advisors first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
MCF Advisors's Melinta Therapeutics, Inc. Common Stock position peaked at $6K in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on MCF Advisors's 13F filing for Q1 2020, filed 24 Apr 2020.